Seropositivity of SARS-CoV-2 in the Population of Kazakhstan: A Nationwide Laboratory-Based Surveillance

Yuliya Semenova, Zhanna Kalmatayeva, Ainash Oshibayeva, Saltanat Mamyrbekova, Aynura Kudirbekova, Ardak Nurbakyt, Ardak Baizhaxynova, Paolo Colet, Natalya Glushkova, Alexandr Ivankov and Antonio Sarria-Santamera
Additional contact information
Yuliya Semenova: Department of Neurology, Ophthalmology and Otolaryngology, Semey Medical University, Semey 071400, Kazakhstan
Zhanna Kalmatayeva: School of Medicine, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan
Ainash Oshibayeva: Administrative Office, Khoja Akhmet Yassawi International Kazakh-Turkish University, Turkestan 161204, Kazakhstan
Saltanat Mamyrbekova: School of Medicine, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan
Aynura Kudirbekova: Invitro-Kazakhstan Laboratory, Medical Department, Almaty 050000, Kazakhstan
Ardak Nurbakyt: Department of Public Health, Asfendiyarov Kazakh National Medical University, Almaty 050012, Kazakhstan
Ardak Baizhaxynova: Department of Medicine, Nazarbayev University School of Medicine, Nur-Sultan 020000, Kazakhstan
Paolo Colet: Department of Medicine, Nazarbayev University School of Medicine, Nur-Sultan 020000, Kazakhstan
Natalya Glushkova: School of Medicine, Al-Farabi Kazakh National University, Almaty 050040, Kazakhstan
Alexandr Ivankov: Independent Researcher, Almaty 050000, Kazakhstan
Antonio Sarria-Santamera: Department of Medicine, Nazarbayev University School of Medicine, Nur-Sultan 020000, Kazakhstan

IJERPH, 2022, vol. 19, issue 4, 1-14

Abstract: The data on seroprevalence of anti-SARS-CoV-2 antibodies in Kazakhstani population are non-existent, but are needed for planning of public health interventions targeted to COVID-19 containment. The aim of the study was to estimate the seropositivity of SARS-CoV-2 infection in the Kazakhstani population from 2020 to 2021. We relied on the data obtained from the results from “IN VITRO” laboratories of enzyme-linked immunosorbent assays for class G immunoglobulins (IgG) and class M (IgM) to SARS-CoV-2. The association of COVID-19 seropositivity was assessed in relation to age, gender, and region of residence. Additionally, we related the monitoring of longitudinal seropositivity with COVID-19 statistics obtained from Our World in Data. The total numbers of tests were 68,732 for SARS-CoV-2 IgM and 85,346 for IgG, of which 22% and 63% were positive, respectively. The highest rates of positive anti-SARS-CoV-2 IgM results were seen during July/August 2020. The rate of IgM seropositivity was the lowest on 25 October 2020 (2%). The lowest daily rate of anti-SARS-CoV-2 IgG was 17% (13 December 2020), while the peak of IgG seropositivity was seen on 6 June 2021 (84%). A longitudinal serological study should be envisaged to facilitate understanding of the dynamics of the epidemiological situation and to forecast future scenarios.

Keywords: COVID-19; Kazakhstan; seropositivity; surveillance (search for similar items in EconPapers)
JEL-codes: I I1 I3 Q Q5 (search for similar items in EconPapers)
Date: 2022
References: View complete reference list from CitEc
Citations:

Downloads: (external link)
https://www.mdpi.com/1660-4601/19/4/2263/pdf (application/pdf)
https://www.mdpi.com/1660-4601/19/4/2263/ (text/html)

Related works:
This item may be available elsewhere in EconPapers: Search for items with the same title.

Export reference: BibTeX RIS (EndNote, ProCite, RefMan) HTML/Text

Persistent link: https://EconPapers.repec.org/RePEc:gam:jijerp:v:19:y:2022:i:4:p:2263-:d:751328

Access Statistics for this article

IJERPH is currently edited by Ms. Jenna Liu

More articles in IJERPH from MDPI
Bibliographic data for series maintained by MDPI Indexing Manager ().